Trial Profile

A Phase 1 study of oral formulation of Foralumab to healthy volunteers for the treatment of Crohn's disease and NASH

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Foralumab (Primary)
Indications Crohn's disease; Non-alcoholic steatohepatitis
Focus Adverse reactions

Most Recent Events

29 Dec 2022 According to a Tiziana Life Sciences media release, this study was the first multiple-dose study with orally administered enteric-coated capsules of foralumab in patients with Crohns disease. Due to the refocus of the company subsequent to the first six months of 2022, this study has been placed on hold.
29 Dec 2022 According to a Tiziana Life Sciences media release, the study completion is targeted for the fourth quarter of 2022.
09 Jan 2020 Results presented in a Tiziana Life Sciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com